tldrdailynews.com logo

GLP-1 weight‑loss drugs: where does potency become a risk?

1 min read
Source: The Washington Post
GLP-1 weight‑loss drugs: where does potency become a risk?
Photo: The Washington Post
TL;DR

Eli Lilly’s experimental GLP-1 drug retatrutide produced an average 28% weight loss in obese patients, a striking boost over existing GLP-1 therapies, but doctors warn that greater potency can bring new safety risks; the company expects to file for FDA approval by 2026.

Topics:businesshealth#clinical-trials#eli-lilly#health#obesity#prescription-drugs#weight-loss
Share this article
  1. An experimental GLP-1 pushes the limits of weight loss. There are risks.  The Washington Post
  2. Experimental Drug Yields Dramatic Weight Loss  The New York Times
  3. Eli Lilly says next-generation weight loss drug clears crucial obesity trial  CNBC
  4. Eli Lilly (LLY) Unveils Obesity Data That Could Raise The Bar For The Entire Industry  Yahoo Finance
  5. Eli Lilly touts new weight-loss shot, says stronger than old GLP-1s  USA Today

Want the full story? Read the original reporting

Read on The Washington Post